Dr. He Huang 黄河
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology, including chemotherapy, targeted therapy, and comprehensive treatment. Specializes in lymphoma and head and neck tumors, with a focus on anticancer drug research.
Dr. Huang holds an MD and is a doctoral supervisor. Graduated from Sun Yat-sen University in June 1998. Completed advanced training at the First Affiliated Hospital of Sun Yat-sen University (1998–1999). Joined the medical oncology department of Sun Yat-sen University Cancer Center in September 1999. Promoted to attending physician in December 2005, associate chief physician in December 2014, and received a doctoral degree in June 2015.
Professional roles
- Secretary-General, China South-West Oncology Group (CSWOG)
- Secretary, Lymphoma Group, Oncology Branch, Chinese Medical Association
- Secretary, Oncology Branch, Guangdong Medical Association
Name order: in Chinese the family name comes first (Huang He). Papers usually list the name as He Huang or Huang H.
Selected publications
135 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Gynecol Oncol, 2026 (senior author): Adjuvant sandwich therapy is associated with improved survival in stage III-IVA endometrial cancer: a network meta-analysis. PubMed 42108734
- Cancer Med, 2026 (senior author): Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. PubMed 42014937
- Clin Nucl Med, 2025 (senior author): Primary Extranodal Natural Killer/T-cell Lymphoma of the Bladder on 18 F-FDG PET/CT. PubMed 40359004
- Heliyon, 2025 (first author): Comprehensive analyses reveal the promising value of gasdermins as prognostic biomarkers and immunotherapeutic targets in head and neck squamous cell carcinoma. PubMed 39807507
- Ann Hematol, 2025 (senior author): Risk stratification based on changes in the standard maximal uptake value on PET/CT and the plasma Epstein‒Barr virus (EBV) DNA status after two cycles of chemotherapy for extranodal NK-/T-cell lymphoma. PubMed 39725700
- J Hematol Oncol, 2024 (first author): Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress. PubMed 39639359
- Discov Oncol, 2024 (senior author): Molecular subtypes and nomogram for predicting the prognosis of cervical cancer based on a matrix-immune signature. PubMed 39230769
- Exp Hematol Oncol, 2024 (first author): Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting. PubMed 38649997
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion